This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

These 3 Insider Favorites Are Trading Significantly Below Target Price

Insiders, naturally, work at the companies in question and have more knowledge about the firm than outsiders, which is why their buying activity is carefully monitored by the investing community.

When they put their own money on the line to purchase their company’s shares it indicates they are bullish about the firm’s future, and believe current share price is undervalued.

[Related: Hedge Funds are Buying Up These 9 Stocks Trading Below Target Price]

Likewise, if a pool of analysts have placed their most pessimistic target price well above current values, it is a sign stocks are trading below their fair value.

These considerations went into creating the list below. These stocks have seen significant insider buying activity in the past six months, and are currently trading below their most pessimistic target price.

EXCLUSIVE OFFER: Jim Cramer’s Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he’s trading today with a 14-day FREE pass.

Regarding target price: We only focused on companies that have more than 5 analyst target prices (to make sure we only focus on companies that have decent analyst coverage). We were left with the three stocks listed in detail below.  List Average 1-Year Return: -26%:

1. Keynote Systems Inc. ( KEYN): Provides Internet and mobile cloud monitoring solutions worldwide. Market cap at $260.21M, most recent closing price at $14.48. Of the 5 analysts that have set a target price on the stock, the lowest price target stands at $17. This implies a potential upside of 17.40% from current levels around $14.48. Over the last six months, insiders were net buyers of 561,662 shares, which represents about 4.24% of the company’s 13.25M share float.

 

2. MannKind Corp. ( MNKD): Focuses on the discovery, development, and commercialization of therapeutic products for diabetes and cancer. Market cap at $636.57M, most recent closing price at $2.59. Of the 6 analysts that have set a target price on the stock, the lowest price target stands at $3. This implies a potential upside of 15.83% from current levels around $2.59. Over the last six months, insiders were net buyers of 31,269,350 shares, which represents about 33.24% of the company’s 94.08M share float.

 

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,034.93 +208.63 1.17%
S&P 500 2,100.40 +19.22 0.92%
NASDAQ 4,994.6020 +62.7870 1.27%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs